ENGNW: the balance sheet

MyFinsight

enGene Therapeutics Inc. (ENGNW)

Balance Sheets	2026-04-30	2026-01-31	2025-10-31	2025-07-31
Cash and cash equivalents	29,827	36,613	50,152	32,623
Marketable securities - short term	228,638	239,335	143,584	169,290
Restricted investments	75	74	79	72
Investment tax credits receivable	822	1,197	927	709
Prepaid and other current assets	10,638	11,997	6,649	8,618
Total current assets	270,000	289,216	201,391	211,312
Marketable securities - long term	26,709	36,601	8,522	23,011
Property and equipment, net	2,335	2,441	2,477	1,879
Operating lease right of use asset	7,105	7,470	7,716	7,969
Other assets	1,375	1,385	1,362	1,379
Total assets	307,524	337,113	221,468	245,550

Accounts payable	1,793	2,435	6,688	2,384
Accrued expenses and other current liabilities	17,212	19,668	15,275	11,117
Operating lease liabilities, current	2,287	2,318	2,014	1,527
Current portion of note payable	193	188	8,002	5,412
Total current liabilities	21,485	24,609	31,979	20,440
Note payable, net of current portion	24,910	24,736	15,324	17,706
Operating lease liabilities, net of current portion	5,961	6,222	6,455	6,732
Liabilities, total	52,356	55,567	53,758	44,878
Common shares, no par value unlimited shares authorized, 66,989,466 and 52,018,658 shares issued and outstanding as of april 30, 2026 and october 31, 2025, respectively	631,995	631,992	513,281	510,164
Additional paid-in capital	56,325	52,180	27,349	25,869
Accumulated other comprehensive loss	-1,141	-842	-888	-1,209
Accumulated deficit	-432,011	-401,784	-372,032	-334,152
Total shareholder's equity	255,168	281,546	167,710	200,672
Total liabilities and shareholders' equity	307,524	337,113	221,468	245,550

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.